The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Indonesia to ink Pfizer, AstraZeneca vaccine deals as awaits Sinovac clearance

Tue, 29th Dec 2020 11:38

(Recasts, adds vox pops on vaccine hesitancy)

By Stanley Widianto and Yuddy Cahya Budiman

JAKARTA, Dec 29 (Reuters) - Indonesia is poised to secure
coronavirus vaccines from Pfizer and AstraZeneca, the health
minister said on Tuesday, as it awaits authorisation to begin
its inoculation programme with a third drug, by China's Sinovac.

Budi Gunadi Sadikin said a 50-million-dose deal with
AstraZeneca would be finalised before the end of the
year, and one of the same size with Pfizer in the first
week of January.

The first shots for both those drugs, which have gained
regulatory approval in many western countries, are not scheduled
to arrive for months, the minister told his first news
conference.

So Indonesia plans to start vaccinations with the Sinovac
treatment, of which it secured 1.2 million doses this
month and expects 1.8 million more in January, once it gains
emergency use clearance.

Interim results from its phase III trial are expected to be
delivered to Indonesia's Food and Drug Agency next month.

Budi said the country's 1.3 million front-line health
workers would get priority in the first wave of vaccinations
between January and April. "They are the most important group of
people in our battle against the pandemic," he told a news
conference.

The world's fourth most populous country has had over
727,000 confirmed COVID cases and 21,700 deaths, among Asia's
highest tallies.

Public servants will be next in line for shots, with those
in infection "red-zones" aged between 18 and 59 prioritised in a
second round of vaccinations.

Indonesia is focusing its programme on that age range rather
than the elderly in an effort to safeguard the working
population.

Bambang Heriyanto, corporate secretary of state-owned
drugmaker Bio Farma, said that strategy would allow Indonesia to
reach herd immunity.

Including Tuesday's announcement, Indonesia has secured 329
million vaccine doses, including about 125 million from Sinovac,
50 million from Novavax and 54 million from global vaccine
programme COVAX.

The AstraZeneca vaccines are expected to arrive in the
second quarter of 2021 and Pfizer's in the third quarter,
according to a slide presentation by Budi.

The companies were not immediately available for comment.

IS IT SAFE? IS IT HALAL?

The vaccine deals met with mixed reactions on the streets of
the capital Jakarta on Tuesday.

"There's lots of diseases with no cure, but there's already
(a) cure for COVID," said 25-year-old radio announcer Cindy
Lauw, "I'm just wary."

Suhaimi, a 55-year-old retiree, said he would await trial
results, and news about whether the vaccine was permitted under
Islam.

A December survey by Indonesian pollster Saiful Mujani
Research and Consulting showed 37% of 1,202 respondents were
willing to be vaccinated, while 40% would consider it and 17%
would refuse.

While acknowledging the essential role of vaccinations,
epidemiologist Pandu Riono warned against over-reliance on them.

"Vaccines are the second step in prevention, the first is
behaviour and surveillance, testing, contact tracing and
isolation," he said.
(Additional reporting by Angie Teo;
Writing by Kate Lamb;
Editing by Martin Petty, Robert Birsel and John Stonestreet)

More News
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.